Peptone
Peptone is a biotechnology company specializing in the design of novel small-molecule therapeutics that selectively target intrinsically disordered proteins (IDPs), which are challenging to model and drug using traditional methods. The company leverages a unique combination of bespoke mass spectrometry, next-generation machine learning, and protein disorder laboratory expertise to identify and exploit druggable pockets in disordered proteins. Their proprietary product engine integrates physics, molecular biology, and supercomputing to enable rapid small molecule design, with capabilities including experimental structure generation via generative AI and molecular dynamics, AI-driven binder design producing billions of candidate molecules weekly, and advanced biophysical laboratory testing for lead selection. Peptone's approach addresses a significant unmet need in drug discovery by targeting the 6,200 intrinsically disordered human proteins that current technologies like AlphaFold 3 cannot model, positioning the company as a pioneer in this emerging therapeutic area.
Peptone
Peptone is a biotechnology company specializing in the design of novel small-molecule therapeutics that selectively target intrinsically disordered proteins (IDPs), which are challenging to model and drug using traditional methods. The company leverages a unique combination of bespoke mass spectrometry, next-generation machine learning, and protein disorder laboratory expertise to identify and exploit druggable pockets in disordered proteins. Their proprietary product engine integrates physics, molecular biology, and supercomputing to enable rapid small molecule design, with capabilities including experimental structure generation via generative AI and molecular dynamics, AI-driven binder design producing billions of candidate molecules weekly, and advanced biophysical laboratory testing for lead selection. Peptone's approach addresses a significant unmet need in drug discovery by targeting the 6,200 intrinsically disordered human proteins that current technologies like AlphaFold 3 cannot model, positioning the company as a pioneer in this emerging therapeutic area.